Prevention of herpes simplex virus type 2 transmission with antiviral therapy

Lawrence Corey, Rhoda Ashley, J. McCloskey, I. Denham, J. Patten, C. Pell, R. Waddell, C. T. Sodre, C. Bouchard, F. J. Diaz-Mitoma, M. G. Lassonde, B. Romanowski, S. L. Sacks, S. Trottler, W. Gubelin, A. Guglielmetti, J. Diaz, N. Rubiano, J. Roed-Petersen, K. Thestrup-Pedersen & 79 others H. C. Wulff, K. Kivimagi, A. Poder, J. Paavonen, S. Saari, A. L. Simpanen, P. Morel, J. P. Ortonne, E. Cardamakis, O. Mourelou, J. Bornstein, M. Dolitzky, B. Dainys, A. Laiskonis, R. G. Soto, V. H. Pulido Olivares, I. Cairo, V. Arama, V. Balasoiu, M. Capalna, C. Giurcaneanu, S. Popescu, V. Tarlea, A. Koubanova, L. Martchenko, T. Semenova, L. Stratchounsky, J. Ballesteros, J. A. Varela, A. Strand, N. Atakan, G. Ozarmagan, G. M. Adkins, D. A. Baker, K. R. Beutner, R. A. Beyerlein, R. Brady, M. Cabezas-Mijuste, S. Clark, M. Conant, L. Corey, M. A. Drehobl, J. Douglas, S. Faro, Kenneth Fife, S. Funk, D. Gartman, G. Garza, D. C. Hart, J. A. Holmes, W. D. Koltun, S. J. Kraus, T. Kurtz, M. A. Landwermeyer, P. A. Leone, M. J. Levin, T. C. Marbury, S. I. Marlowe, A. Marques, G. Mertz, R. Nett, B. Pogue, D. M. Poretz, J. Rosen, D. H. Rowe, G. Salazar, T. W. Schacker, M. Seraly, R. P. Spencer, J. Stern, S. Stone, E. Thomas, S. K. Tyring, A. Wald, T. Warren, D. A. Whiting, M. L. Wiener, H. Wiesenfeld, C. Bowman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Worldwide, herpes simplex virus type 2 (HSV-2) infection is the biggest cause of genital ulcer disease, and is responsible for the majority of cases of genital herpes. The risk of transmitting genital herpes to a partner is one of the leading causes of psychological distress for those with the disease. Antiviral compounds available for the treatment of genital herpes are known to reduce clinical recurrence rates and HSV shedding. This understanding provided impetus for a randomized, placebo-controlled study to assess the ability to interrupt transmission of HSV using oral valaciclovir therapy (500 mg, once daily). The study enrolled 1484 immunocompetent, heterosexual, monogamous couples in stable relationships where both partners were aware of the source partner's infection and the source partner had symptomatic genital herpes. Valaciclovir reduced the risk of transmitting HSV-2 infection by 48%. Furthermore, valaciclovir reduced the risk of clinical disease in the susceptible partner by 75%. As a result, the International Herpes Management Forum (IHMF) now recommends that physicians offer suppressive valaciclovir therapy to immunocompetent individuals concerned about transmitting genital herpes to a heterosexual partner, and advises safer sex behaviour, including the use of condoms, to prevent genital herpes transmission.

Original languageEnglish (US)
JournalHerpes
Volume11
Issue numberSUPPL. 3
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

valacyclovir
Herpes Genitalis
Human Herpesvirus 2
Antiviral Agents
Heterosexuality
Virus Diseases
Therapeutics
Safe Sex
Aptitude
Condoms
Sexual Behavior
Ulcer
Placebos
Psychology
Physicians
Recurrence
Infection

Keywords

  • Antiviral therapy
  • Behavioural strategies
  • Genital ulcer disease
  • Herpes simplex virus
  • Heterosexual
  • HSV shedding
  • STI
  • Transmission
  • Valaciclovir

ASJC Scopus subject areas

  • Virology
  • Dermatology

Cite this

Corey, L., Ashley, R., McCloskey, J., Denham, I., Patten, J., Pell, C., ... Bowman, C. (2004). Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Herpes, 11(SUPPL. 3).

Prevention of herpes simplex virus type 2 transmission with antiviral therapy. / Corey, Lawrence; Ashley, Rhoda; McCloskey, J.; Denham, I.; Patten, J.; Pell, C.; Waddell, R.; Sodre, C. T.; Bouchard, C.; Diaz-Mitoma, F. J.; Lassonde, M. G.; Romanowski, B.; Sacks, S. L.; Trottler, S.; Gubelin, W.; Guglielmetti, A.; Diaz, J.; Rubiano, N.; Roed-Petersen, J.; Thestrup-Pedersen, K.; Wulff, H. C.; Kivimagi, K.; Poder, A.; Paavonen, J.; Saari, S.; Simpanen, A. L.; Morel, P.; Ortonne, J. P.; Cardamakis, E.; Mourelou, O.; Bornstein, J.; Dolitzky, M.; Dainys, B.; Laiskonis, A.; Soto, R. G.; Pulido Olivares, V. H.; Cairo, I.; Arama, V.; Balasoiu, V.; Capalna, M.; Giurcaneanu, C.; Popescu, S.; Tarlea, V.; Koubanova, A.; Martchenko, L.; Semenova, T.; Stratchounsky, L.; Ballesteros, J.; Varela, J. A.; Strand, A.; Atakan, N.; Ozarmagan, G.; Adkins, G. M.; Baker, D. A.; Beutner, K. R.; Beyerlein, R. A.; Brady, R.; Cabezas-Mijuste, M.; Clark, S.; Conant, M.; Corey, L.; Drehobl, M. A.; Douglas, J.; Faro, S.; Fife, Kenneth; Funk, S.; Gartman, D.; Garza, G.; Hart, D. C.; Holmes, J. A.; Koltun, W. D.; Kraus, S. J.; Kurtz, T.; Landwermeyer, M. A.; Leone, P. A.; Levin, M. J.; Marbury, T. C.; Marlowe, S. I.; Marques, A.; Mertz, G.; Nett, R.; Pogue, B.; Poretz, D. M.; Rosen, J.; Rowe, D. H.; Salazar, G.; Schacker, T. W.; Seraly, M.; Spencer, R. P.; Stern, J.; Stone, S.; Thomas, E.; Tyring, S. K.; Wald, A.; Warren, T.; Whiting, D. A.; Wiener, M. L.; Wiesenfeld, H.; Bowman, C.

In: Herpes, Vol. 11, No. SUPPL. 3, 08.2004.

Research output: Contribution to journalArticle

Corey, L, Ashley, R, McCloskey, J, Denham, I, Patten, J, Pell, C, Waddell, R, Sodre, CT, Bouchard, C, Diaz-Mitoma, FJ, Lassonde, MG, Romanowski, B, Sacks, SL, Trottler, S, Gubelin, W, Guglielmetti, A, Diaz, J, Rubiano, N, Roed-Petersen, J, Thestrup-Pedersen, K, Wulff, HC, Kivimagi, K, Poder, A, Paavonen, J, Saari, S, Simpanen, AL, Morel, P, Ortonne, JP, Cardamakis, E, Mourelou, O, Bornstein, J, Dolitzky, M, Dainys, B, Laiskonis, A, Soto, RG, Pulido Olivares, VH, Cairo, I, Arama, V, Balasoiu, V, Capalna, M, Giurcaneanu, C, Popescu, S, Tarlea, V, Koubanova, A, Martchenko, L, Semenova, T, Stratchounsky, L, Ballesteros, J, Varela, JA, Strand, A, Atakan, N, Ozarmagan, G, Adkins, GM, Baker, DA, Beutner, KR, Beyerlein, RA, Brady, R, Cabezas-Mijuste, M, Clark, S, Conant, M, Corey, L, Drehobl, MA, Douglas, J, Faro, S, Fife, K, Funk, S, Gartman, D, Garza, G, Hart, DC, Holmes, JA, Koltun, WD, Kraus, SJ, Kurtz, T, Landwermeyer, MA, Leone, PA, Levin, MJ, Marbury, TC, Marlowe, SI, Marques, A, Mertz, G, Nett, R, Pogue, B, Poretz, DM, Rosen, J, Rowe, DH, Salazar, G, Schacker, TW, Seraly, M, Spencer, RP, Stern, J, Stone, S, Thomas, E, Tyring, SK, Wald, A, Warren, T, Whiting, DA, Wiener, ML, Wiesenfeld, H & Bowman, C 2004, 'Prevention of herpes simplex virus type 2 transmission with antiviral therapy', Herpes, vol. 11, no. SUPPL. 3.
Corey L, Ashley R, McCloskey J, Denham I, Patten J, Pell C et al. Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Herpes. 2004 Aug;11(SUPPL. 3).
Corey, Lawrence ; Ashley, Rhoda ; McCloskey, J. ; Denham, I. ; Patten, J. ; Pell, C. ; Waddell, R. ; Sodre, C. T. ; Bouchard, C. ; Diaz-Mitoma, F. J. ; Lassonde, M. G. ; Romanowski, B. ; Sacks, S. L. ; Trottler, S. ; Gubelin, W. ; Guglielmetti, A. ; Diaz, J. ; Rubiano, N. ; Roed-Petersen, J. ; Thestrup-Pedersen, K. ; Wulff, H. C. ; Kivimagi, K. ; Poder, A. ; Paavonen, J. ; Saari, S. ; Simpanen, A. L. ; Morel, P. ; Ortonne, J. P. ; Cardamakis, E. ; Mourelou, O. ; Bornstein, J. ; Dolitzky, M. ; Dainys, B. ; Laiskonis, A. ; Soto, R. G. ; Pulido Olivares, V. H. ; Cairo, I. ; Arama, V. ; Balasoiu, V. ; Capalna, M. ; Giurcaneanu, C. ; Popescu, S. ; Tarlea, V. ; Koubanova, A. ; Martchenko, L. ; Semenova, T. ; Stratchounsky, L. ; Ballesteros, J. ; Varela, J. A. ; Strand, A. ; Atakan, N. ; Ozarmagan, G. ; Adkins, G. M. ; Baker, D. A. ; Beutner, K. R. ; Beyerlein, R. A. ; Brady, R. ; Cabezas-Mijuste, M. ; Clark, S. ; Conant, M. ; Corey, L. ; Drehobl, M. A. ; Douglas, J. ; Faro, S. ; Fife, Kenneth ; Funk, S. ; Gartman, D. ; Garza, G. ; Hart, D. C. ; Holmes, J. A. ; Koltun, W. D. ; Kraus, S. J. ; Kurtz, T. ; Landwermeyer, M. A. ; Leone, P. A. ; Levin, M. J. ; Marbury, T. C. ; Marlowe, S. I. ; Marques, A. ; Mertz, G. ; Nett, R. ; Pogue, B. ; Poretz, D. M. ; Rosen, J. ; Rowe, D. H. ; Salazar, G. ; Schacker, T. W. ; Seraly, M. ; Spencer, R. P. ; Stern, J. ; Stone, S. ; Thomas, E. ; Tyring, S. K. ; Wald, A. ; Warren, T. ; Whiting, D. A. ; Wiener, M. L. ; Wiesenfeld, H. ; Bowman, C. / Prevention of herpes simplex virus type 2 transmission with antiviral therapy. In: Herpes. 2004 ; Vol. 11, No. SUPPL. 3.
@article{b65122fb442b48c6aef3fcf911832cf1,
title = "Prevention of herpes simplex virus type 2 transmission with antiviral therapy",
abstract = "Worldwide, herpes simplex virus type 2 (HSV-2) infection is the biggest cause of genital ulcer disease, and is responsible for the majority of cases of genital herpes. The risk of transmitting genital herpes to a partner is one of the leading causes of psychological distress for those with the disease. Antiviral compounds available for the treatment of genital herpes are known to reduce clinical recurrence rates and HSV shedding. This understanding provided impetus for a randomized, placebo-controlled study to assess the ability to interrupt transmission of HSV using oral valaciclovir therapy (500 mg, once daily). The study enrolled 1484 immunocompetent, heterosexual, monogamous couples in stable relationships where both partners were aware of the source partner's infection and the source partner had symptomatic genital herpes. Valaciclovir reduced the risk of transmitting HSV-2 infection by 48{\%}. Furthermore, valaciclovir reduced the risk of clinical disease in the susceptible partner by 75{\%}. As a result, the International Herpes Management Forum (IHMF) now recommends that physicians offer suppressive valaciclovir therapy to immunocompetent individuals concerned about transmitting genital herpes to a heterosexual partner, and advises safer sex behaviour, including the use of condoms, to prevent genital herpes transmission.",
keywords = "Antiviral therapy, Behavioural strategies, Genital ulcer disease, Herpes simplex virus, Heterosexual, HSV shedding, STI, Transmission, Valaciclovir",
author = "Lawrence Corey and Rhoda Ashley and J. McCloskey and I. Denham and J. Patten and C. Pell and R. Waddell and Sodre, {C. T.} and C. Bouchard and Diaz-Mitoma, {F. J.} and Lassonde, {M. G.} and B. Romanowski and Sacks, {S. L.} and S. Trottler and W. Gubelin and A. Guglielmetti and J. Diaz and N. Rubiano and J. Roed-Petersen and K. Thestrup-Pedersen and Wulff, {H. C.} and K. Kivimagi and A. Poder and J. Paavonen and S. Saari and Simpanen, {A. L.} and P. Morel and Ortonne, {J. P.} and E. Cardamakis and O. Mourelou and J. Bornstein and M. Dolitzky and B. Dainys and A. Laiskonis and Soto, {R. G.} and {Pulido Olivares}, {V. H.} and I. Cairo and V. Arama and V. Balasoiu and M. Capalna and C. Giurcaneanu and S. Popescu and V. Tarlea and A. Koubanova and L. Martchenko and T. Semenova and L. Stratchounsky and J. Ballesteros and Varela, {J. A.} and A. Strand and N. Atakan and G. Ozarmagan and Adkins, {G. M.} and Baker, {D. A.} and Beutner, {K. R.} and Beyerlein, {R. A.} and R. Brady and M. Cabezas-Mijuste and S. Clark and M. Conant and L. Corey and Drehobl, {M. A.} and J. Douglas and S. Faro and Kenneth Fife and S. Funk and D. Gartman and G. Garza and Hart, {D. C.} and Holmes, {J. A.} and Koltun, {W. D.} and Kraus, {S. J.} and T. Kurtz and Landwermeyer, {M. A.} and Leone, {P. A.} and Levin, {M. J.} and Marbury, {T. C.} and Marlowe, {S. I.} and A. Marques and G. Mertz and R. Nett and B. Pogue and Poretz, {D. M.} and J. Rosen and Rowe, {D. H.} and G. Salazar and Schacker, {T. W.} and M. Seraly and Spencer, {R. P.} and J. Stern and S. Stone and E. Thomas and Tyring, {S. K.} and A. Wald and T. Warren and Whiting, {D. A.} and Wiener, {M. L.} and H. Wiesenfeld and C. Bowman",
year = "2004",
month = "8",
language = "English (US)",
volume = "11",
journal = "Herpes",
issn = "0969-7667",
publisher = "Cambridge Medical Publications",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Prevention of herpes simplex virus type 2 transmission with antiviral therapy

AU - Corey, Lawrence

AU - Ashley, Rhoda

AU - McCloskey, J.

AU - Denham, I.

AU - Patten, J.

AU - Pell, C.

AU - Waddell, R.

AU - Sodre, C. T.

AU - Bouchard, C.

AU - Diaz-Mitoma, F. J.

AU - Lassonde, M. G.

AU - Romanowski, B.

AU - Sacks, S. L.

AU - Trottler, S.

AU - Gubelin, W.

AU - Guglielmetti, A.

AU - Diaz, J.

AU - Rubiano, N.

AU - Roed-Petersen, J.

AU - Thestrup-Pedersen, K.

AU - Wulff, H. C.

AU - Kivimagi, K.

AU - Poder, A.

AU - Paavonen, J.

AU - Saari, S.

AU - Simpanen, A. L.

AU - Morel, P.

AU - Ortonne, J. P.

AU - Cardamakis, E.

AU - Mourelou, O.

AU - Bornstein, J.

AU - Dolitzky, M.

AU - Dainys, B.

AU - Laiskonis, A.

AU - Soto, R. G.

AU - Pulido Olivares, V. H.

AU - Cairo, I.

AU - Arama, V.

AU - Balasoiu, V.

AU - Capalna, M.

AU - Giurcaneanu, C.

AU - Popescu, S.

AU - Tarlea, V.

AU - Koubanova, A.

AU - Martchenko, L.

AU - Semenova, T.

AU - Stratchounsky, L.

AU - Ballesteros, J.

AU - Varela, J. A.

AU - Strand, A.

AU - Atakan, N.

AU - Ozarmagan, G.

AU - Adkins, G. M.

AU - Baker, D. A.

AU - Beutner, K. R.

AU - Beyerlein, R. A.

AU - Brady, R.

AU - Cabezas-Mijuste, M.

AU - Clark, S.

AU - Conant, M.

AU - Corey, L.

AU - Drehobl, M. A.

AU - Douglas, J.

AU - Faro, S.

AU - Fife, Kenneth

AU - Funk, S.

AU - Gartman, D.

AU - Garza, G.

AU - Hart, D. C.

AU - Holmes, J. A.

AU - Koltun, W. D.

AU - Kraus, S. J.

AU - Kurtz, T.

AU - Landwermeyer, M. A.

AU - Leone, P. A.

AU - Levin, M. J.

AU - Marbury, T. C.

AU - Marlowe, S. I.

AU - Marques, A.

AU - Mertz, G.

AU - Nett, R.

AU - Pogue, B.

AU - Poretz, D. M.

AU - Rosen, J.

AU - Rowe, D. H.

AU - Salazar, G.

AU - Schacker, T. W.

AU - Seraly, M.

AU - Spencer, R. P.

AU - Stern, J.

AU - Stone, S.

AU - Thomas, E.

AU - Tyring, S. K.

AU - Wald, A.

AU - Warren, T.

AU - Whiting, D. A.

AU - Wiener, M. L.

AU - Wiesenfeld, H.

AU - Bowman, C.

PY - 2004/8

Y1 - 2004/8

N2 - Worldwide, herpes simplex virus type 2 (HSV-2) infection is the biggest cause of genital ulcer disease, and is responsible for the majority of cases of genital herpes. The risk of transmitting genital herpes to a partner is one of the leading causes of psychological distress for those with the disease. Antiviral compounds available for the treatment of genital herpes are known to reduce clinical recurrence rates and HSV shedding. This understanding provided impetus for a randomized, placebo-controlled study to assess the ability to interrupt transmission of HSV using oral valaciclovir therapy (500 mg, once daily). The study enrolled 1484 immunocompetent, heterosexual, monogamous couples in stable relationships where both partners were aware of the source partner's infection and the source partner had symptomatic genital herpes. Valaciclovir reduced the risk of transmitting HSV-2 infection by 48%. Furthermore, valaciclovir reduced the risk of clinical disease in the susceptible partner by 75%. As a result, the International Herpes Management Forum (IHMF) now recommends that physicians offer suppressive valaciclovir therapy to immunocompetent individuals concerned about transmitting genital herpes to a heterosexual partner, and advises safer sex behaviour, including the use of condoms, to prevent genital herpes transmission.

AB - Worldwide, herpes simplex virus type 2 (HSV-2) infection is the biggest cause of genital ulcer disease, and is responsible for the majority of cases of genital herpes. The risk of transmitting genital herpes to a partner is one of the leading causes of psychological distress for those with the disease. Antiviral compounds available for the treatment of genital herpes are known to reduce clinical recurrence rates and HSV shedding. This understanding provided impetus for a randomized, placebo-controlled study to assess the ability to interrupt transmission of HSV using oral valaciclovir therapy (500 mg, once daily). The study enrolled 1484 immunocompetent, heterosexual, monogamous couples in stable relationships where both partners were aware of the source partner's infection and the source partner had symptomatic genital herpes. Valaciclovir reduced the risk of transmitting HSV-2 infection by 48%. Furthermore, valaciclovir reduced the risk of clinical disease in the susceptible partner by 75%. As a result, the International Herpes Management Forum (IHMF) now recommends that physicians offer suppressive valaciclovir therapy to immunocompetent individuals concerned about transmitting genital herpes to a heterosexual partner, and advises safer sex behaviour, including the use of condoms, to prevent genital herpes transmission.

KW - Antiviral therapy

KW - Behavioural strategies

KW - Genital ulcer disease

KW - Herpes simplex virus

KW - Heterosexual

KW - HSV shedding

KW - STI

KW - Transmission

KW - Valaciclovir

UR - http://www.scopus.com/inward/record.url?scp=4344592187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344592187&partnerID=8YFLogxK

M3 - Article

VL - 11

JO - Herpes

JF - Herpes

SN - 0969-7667

IS - SUPPL. 3

ER -